ICD-10 Code C73: Malignant neoplasm of thyroid gland

Key Takeaways

ICD-10 Code C73 is the single billable ICD-10-CM code for malignant neoplasm of the thyroid gland, covering all histological subtypes including papillary, follicular, medullary, and anaplastic thyroid carcinoma.

C73 falls within the C73-C75 code range for malignant neoplasms of thyroid and other endocrine glands, under the broader C00-D49 neoplasms block.

After thyroidectomy or when disease is resolved, switch to Z85.850 (personal history of malignant neoplasm of thyroid gland); using C73 for resolved disease is a common documentation error.

Pabau’s clinical documentation tools and claims management software help oncology and endocrinology practices code C73 accurately and meet payer documentation requirements.

Thyroid cancer claims around 44,000 new diagnoses in the United States each year, according to the CDC’s ICD-10-CM web tool and supporting surveillance data, making accurate diagnosis coding more than a billing formality. A single misassignment between C73 and related codes can trigger claim denials, documentation audits, or incorrect staging records that follow the patient through their entire care pathway.

This reference covers ICD-10 Code C73’s clinical definition, the four major thyroid carcinoma subtypes it encompasses, documentation requirements, related codes, commonly paired CPT codes, and the critical distinction between active malignancy and post-treatment history coding.

ICD-10 Code C73: definition and clinical description

ICD-10 Code C73 designates a malignant neoplasm of the thyroid gland under the ICD-10-CM diagnostic coding framework maintained jointly by the Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS). It is a fully billable, stand-alone diagnosis code, meaning no additional subcode is required to specify the thyroid gland as the primary site.

C73 sits within the C73-C75 code range, which covers malignant neoplasms of thyroid and other endocrine glands. That range itself falls under the broader C00-D49 block for all neoplasm diagnoses, as classified by the World Health Organization. Per the CMS ICD-10 coding guidance, C73 is effective for fiscal year 2026 with no changes to its descriptor or coding logic from prior years.

Four histological subtypes of thyroid carcinoma are all mapped to this single code in ICD-10-CM:

• Papillary thyroid carcinoma – the most common subtype, typically well-differentiated and iodine-responsive
• Follicular thyroid carcinoma – second most common, also differentiated, with a higher tendency for vascular invasion
• Medullary thyroid carcinoma – arises from parafollicular C cells; associated with MEN2 syndromes
• Anaplastic thyroid carcinoma – undifferentiated, aggressive, associated with poor prognosis

ICD-10-CM does not subdivide C73 by histological subtype. All four types are coded identically at the C73 level. The clinical distinction belongs in the medical record narrative, pathology report, and any associated procedure documentation, not in a sub-code that does not exist within the current classification.

Billable status and code range for ICD-10 Code C73

C73 is a valid, billable ICD-10-CM diagnosis code for fiscal year 2026. Unlike many neoplasm chapters where a parent code requires a more specific subcode, C73 has no child codes beneath it. Coders can submit it directly on claims without further specification at the ICD-10-CM level.

Within the C73-C75 block, C73 is the only code that requires no further specification. C74 and C75 each branch into subcodes based on laterality, specific gland location, or associated structures. Coders encountering thyroid malignancy claims should not attempt to apply C74 or C75 logic to C73, as those parent codes govern different anatomical sites entirely.

Pabau’s claims management software allows oncology billing teams to attach C73 to procedures at the point of documentation, reducing the lag between clinical encounter and claim submission that often leads to denied or stale claims.

Documentation requirements for ICD-10 Code C73

Accurate C73 coding begins in the medical record, not at the claim. ICD-10-CM documentation requirements set by CMS and NCHS state that a coded diagnosis must be supported by physician documentation. For C73, that means the record must explicitly name the malignancy of the thyroid gland, not just reference a suspicious nodule, elevated TSH, or abnormal fine needle aspiration biopsy result.

Physicians and clinicians should document the following to support C73 assignment:

• A confirmed diagnosis of malignant neoplasm of the thyroid gland, stated explicitly by the treating or consulting physician
• Histological subtype, where known from pathology (papillary, follicular, medullary, or anaplastic) – even though ICD-10-CM codes all to C73, the record should reflect subtype for clinical continuity
• Laterality and lobe involvement (left, right, isthmus), documented in the narrative even though C73 does not have laterality subcodes
• Current active disease status, confirming this is not a historical or resolved malignancy
• TNM staging or AJCC tumor staging, documented separately but coded using additional staging codes alongside C73

A common audit finding is the use of C73 during surveillance visits where the patient’s thyroid cancer has been fully treated and is in remission. Once a patient has completed treatment and the malignancy is considered resolved, Z85.850 becomes the correct code for subsequent encounters. Continuing to submit C73 post-treatment misrepresents the patient’s current status and can affect insurance continuity and downstream coding accuracy.

For endocrinology and oncology practices handling high volumes of thyroid cancer patients, clinic management software that separates active diagnosis codes from historical flags can prevent this type of error at scale.

Related codes and crosswalks

C73 rarely appears alone on a claim. Understanding the codes that pair with it, or replace it depending on clinical context, is essential for accurate oncology billing. For context on how related ICD-10 neoplasm code ranges function within the broader classification system, the WHO ICD-10 hierarchy provides useful structural context.

C73 vs. Z85.850: active disease vs. personal history

This distinction causes more claim issues than any other C73-adjacent coding decision. C73 applies when the patient has active, confirmed thyroid malignancy. Z85.850 applies when the malignancy has been treated and the patient presents for surveillance, follow-up imaging, or TSH monitoring without evidence of active disease.

The switch point is clinical, not administrative. When a physician documents remission or resolved disease, the coder must transition from C73 to Z85.850. Using C73 at a surveillance visit where remission has been documented may trigger medical necessity reviews and denials from Medicare and commercial payers alike.

Additional codes used alongside C73

Per the ICD-10-CM tabular list “Use Additional” notation for C73, coders should also apply:

• Tumor staging codes – AJCC/TNM pathological staging is documented using additional codes when required by the payer or facility coding policy
• Metastasis codes – if thyroid cancer has spread to lymph nodes or distant sites, code the metastatic site separately (e.g., C77.0 for regional lymph node involvement)
• Exposure and history codes – radiation exposure history may be coded alongside C73 where clinically documented and relevant to the encounter
• Z codes for treatment status – Z08 (encounter for follow-up examination after completed treatment) or Z09 may apply in certain post-treatment encounter contexts

Always verify current payer requirements for additional code submissions, as Medicare Administrative Contractors (MACs) and commercial payers sometimes differ on which supplemental codes they require or accept alongside cancer diagnoses.

Reduce coding errors across your oncology and endocrinology practice

Pabau helps clinic teams attach diagnosis codes at the point of care, track active versus historical diagnoses, and submit cleaner claims from day one.

Book a demo

CPT codes commonly used with C73

Procedure billing for thyroid cancer typically involves surgical, diagnostic, and therapeutic CPT codes paired with C73 as the supporting diagnosis. The pairing must meet medical necessity criteria, meaning the procedure must be clinically indicated for the condition C73 describes. For full fee schedule lookups and RVU values, the AAPC Codify ICD-10-CM reference provides current crosswalk data linking ICD-10 diagnoses to commonly paired CPT codes.

Radioactive iodine (RAI) therapy, used primarily in differentiated (papillary and follicular) thyroid carcinomas after thyroidectomy, is billed through HCPCS codes for the specific radioactive isotope administered. These HCPCS codes pair with C73 for active disease encounters, or with Z85.850 when RAI is given as adjuvant post-treatment rather than as primary cancer therapy. Coders should confirm with the treating nuclear medicine or oncology team which clinical context applies.

Coding compliance and EHR documentation

Payer scrutiny of oncology claims, including thyroid cancer, has increased as Medicare Advantage plans and commercial insurers expand prior authorization requirements for surgical and nuclear medicine procedures. Practices that submit C73 claims need documentation that clearly supports medical necessity at every encounter.

The WHO’s ICD-10 browser provides the international classification framework underlying C73’s CMS-adapted U.S. version. While U.S. payers operate under ICD-10-CM (the clinical modification), understanding the WHO hierarchy helps coders recognize the anatomical logic behind code placement and why C73 has no subcodes at the thyroid level.

Specific documentation risks that coders and compliance teams should monitor:

• Outdated active diagnosis flags – patients who completed thyroidectomy years ago may still have C73 as an active problem list entry in the EHR; this should be updated to Z85.850 post-treatment
• Unsupported staging claims – submitting staging codes alongside C73 without matching pathology documentation in the record
• Concurrent coding of metastasis without documentation – secondary site codes (e.g., C77 lymph node, C78 respiratory/digestive) require explicit physician documentation of metastatic spread
• Incorrect use at surveillance encounters – the most frequent compliance finding in endocrinology audits involving thyroid cancer patients

Robust EHR integration for oncology workflows should include problem list management that distinguishes active malignancy from personal history flags, reducing the risk of C73 persisting incorrectly on claims long after treatment concludes. Protecting patient data security in oncology practices also depends on accurate, up-to-date diagnosis records that reflect current clinical status rather than legacy entries from initial diagnosis visits.

Synonyms and inclusions under C73

The ICD-10-CM tabular list and associated index entries include multiple synonym terms that map to C73. Coders and clinical documentation specialists should recognize these terms in physician notes and route them correctly to C73 rather than searching for a non-existent subcode.

Synonyms confirmed under ICD-10 Code C73 include:

• Anaplastic thyroid carcinoma
• Papillary thyroid carcinoma
• Follicular thyroid carcinoma
• Medullary thyroid carcinoma
• Thyroid carcinoma, NOS (not otherwise specified)
• Malignant thyroid tumor
• Thyroid cancer
• Cancer of the thyroid gland

None of these terms carry their own ICD-10-CM code. When a pathology report or operative note uses any of these terms in the context of confirmed malignancy, C73 is the appropriate code. Coders should not attempt to assign a more specific code at the ICD-10-CM level for subtype differentiation; that level of granularity belongs in the clinical documentation, not the code selection.

Practices managing oncology documentation at scale can use Pabau’s digital forms to capture standardized pathology and diagnosis details at each encounter, making it easier for coding teams to verify the correct code assignment without returning to the physician for clarification.

Conclusion

Thyroid cancer coding looks straightforward on the surface; one code, no subcodes. But the real challenge sits in two places: knowing when to use C73 versus Z85.850, and building documentation habits that make that distinction clear at every encounter. Claims submitted with C73 for patients whose disease has resolved will face payer scrutiny, and the fix requires clinical record updates, not just billing corrections.

Pabau’s clinical documentation tools and integrated claims workflow give endocrinology and oncology teams a single system for managing active diagnoses, tracking treatment phase transitions, and reducing the lag between clinical encounter and clean claim submission. To see how Pabau supports oncology and endocrinology practice documentation, book a demo with the team.

Continue your research

Need guidance on managing complex ICD-10 neoplasm code ranges? Related ICD-10 neoplasm code ranges walks through how adjacent code blocks in the C00-D49 chapter are structured and navigated.

Looking for a practice management platform that integrates billing and documentation? Practice management software covers what to look for when evaluating systems for oncology and specialty practices.

Want to improve patient data handling across your oncology workflows? Patient data security tools outlines the key systems and processes that protect sensitive diagnosis and treatment records.

Frequently Asked Questions